Th2 cell–induced terminal differentiation is driven by IL-3/IL-5/GM-CSF binding to receptors with a common β chain on breast cancer cells, which results in the activation of the signaling transducer and activator of transcription 5 (STAT5) pathway (Broughton et al., 2012). Here, IL3 is linked to breast carcinoma.